StockWatch
·

ALKYL AMINES CHEMICALS LTD.-$ Q2 FY27 Results

ALKYLAMINEQ2 FY27 Results
Filing
Result:Good· Market: Flat#Margin expansion#Broad based
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue490.957.0%26.1%
Total Income501.726.6%26.4%
Expenditure411.630.2%21.9%
PBT90.0927.7%52.4%
Net Profit65.1731.1%51.8%
OPM19.90%5.40pp1.87pp
NPM12.99%4.62pp2.17pp
EPS12.7431.1%51.7%
View full financials

Chemicals name showing strong YoY revenue growth (26.1%) and faster adjusted PAT growth (51.8%) with genuine operating-margin expansion (18.0%→19.9%) driven by core business, but QoQ reversion off an exceptionally strong Q1 base and no verifiable street consensus cap it just below very_good.

Q2 FY-2027 RESULTS · ALKYLAMINE

Alkyl Amines Q2 FY27: PAT +52% YoY as margins expand, but cools 31% QoQ off Q1 peak

PAT +51.77% YoY · revenue +26.08% · margins expanding

03 Nov 2026 · 3 min read
Revenue

₹490.95 Cr

+26.08% YoY

PAT (standalone)

₹65.17 Cr

+51.77% YoY

Net margin

12.99%

+2.2pp YoY

EPS

₹12.74

Alkyl Amines' standalone PAT came in at ₹65.17 Cr on revenue from operations of ₹490.95 Cr for the September 2026 quarter. Year-on-year — the primary read — revenue grew 26.1% (₹389.41 Cr) and PAT grew a faster 51.8% (₹42.94 Cr), with net margin expanding to 13.0% from 10.8% and operating margin to 19.9% from 18.0%. Sequentially the print is softer: revenue fell 7.0% and PAT fell 31.1% against Q1 FY27 (revenue ₹528.01 Cr, PAT ₹94.63 Cr, OPM 25.3%), but Q1 was itself an exceptionally strong base — the company had flagged PAT +91% YoY and margin expansion to 25.3% that quarter — so the QoQ dip reads as reversion rather than fresh deterioration; no exceptional items appear in any of the compared quarters.

The scoreboard

Q2 FY-2027 vs prior quarters

Standalone P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹490.95 Cr-7%+26.1%
Expenses₹411.63 Cr-0.2%+21.9%
PAT₹65.17 Cr-31.14%+51.77%
Net margin12.99%-4.6pp+2.2pp
EPS₹12.74-31.1%+51.7%

The margin bridge sits mostly on operating leverage: cost of materials consumed eased to 53.1% of revenue from operations (versus 59.9% in Q1 and 49.2% a year ago), but employee costs (₹33.95 Cr) and other expenses (₹90.16 Cr) held roughly flat in absolute terms versus Q1 (₹36.31 Cr and ₹90.05 Cr), so the 7% QoQ revenue decline compressed operating margin from Q1's elevated 25.3% to 19.9% — still above the year-ago 18.0%. Tax worked out to ₹24.92 Cr on PBT of ₹90.09 Cr (effective rate 27.7%), in line with recent quarters.

₹
1,529.941,684.841,839.751,994.662,149.561,637.507-3108-2409-1610-0911-03Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹1,637.5, down 6% over the past month of trading.

₹ Cr
035.3370.66105.9949.44Q1 FY26rev ₹406 Cr42.94Q2 FY26rev ₹389 Cr42.26Q3 FY26rev ₹354 Cr45.37Q4 FY26rev ₹387 Cr94.63Q1 FY27rev ₹528 Cr65.17Q2 FY27rev ₹491 Cr
Quarterly standalone PAT, ₹ Crore

For context: this is the second-highest quarterly PAT of the last 6 quarters.

Beyond the headline

What the summary numbers don't show

EPS (basic) ₹12.74 for the quarter, down from ₹18.50 in Q1 FY27, up from ₹8.40 a year ago.

What management guided (4 FY-2026 call)
Management projects 5% to 10% volume growth for the upcoming year, with top-line revenue expected to be significantly higher due to elevated product prices. They express cautious optimism that margins have bottomed out and will see improvement, driven by passing on higher raw material costs. Capex will be limited to co

— This quarter: met

No public analyst consensus for this quarter turned up in search, so vs-street is unknown rather than assumed. Against management's own May 2026 concall guidance — 5-10% volume growth for the year, revenue significantly higher on elevated prices, and margins bottoming out with room to improve — this print is broadly on-track: YoY revenue and margin both moved in the guided direction, though the QoQ pullback means the margin recovery is not yet linear. No management press release commentary was available in the context to cross-check against. Separately, the stock saw a trading-volume spike in early October that drew a BSE clarification request (company confirmed no undisclosed price-sensitive information) — unrelated to this result. On the balance sheet, the company drew ₹19 Cr of secured borrowings for the first time in recent periods and capital work-in-progress rose to ₹159.53 Cr from ₹130.48 Cr, with H1 FY27 capex of ₹36.72 Cr tracking within the ₹80-90 Cr full-year guided band.

  • W1

    Whether OPM holds near the YoY-expanded 18-20% band or reverts further from Q1's 25.3% peak, per management's guidance that margins have bottomed and will improve.

  • W2

    H2 FY27 capex pace against the ₹80-90 Cr full-year guidance, with ₹36.72 Cr spent in H1.

  • W3

    Whether full-year revenue growth tracks management's guided 5-10% volume growth with higher realizations, given this quarter's 7% QoQ revenue dip.

Standalone only — company has no subsidiary/associate/JV this quarter (note 7); no exceptional items in current, Q1 FY27 or year-ago columns; PBT−tax reconciles exactly to reported PAT.

Informational and educational content only. Not investment advice.